OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0050

Varicose Veins Clinical Policy Bulletin

Customize your policy alerts

Sign up for Aetna Policy 0050 alerts

Get alerted when Policy 0050 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity, experimental/investigational, and cosmetic coverage positions for surgical ligation/division/stripping, endovenous ablation (radiofrequency and laser), sclerotherapy (liquid/foam), ambulatory phlebectomy/TriVex, valvular reconstruction, and treatment of incompetent perforating veins; includes required diagnostic ultrasound documentation and size/reflux thresholds and lists applicable CPT/HCPCS/ICD-10 codes.

Policy Summary

PayerAetna

PolicyVaricose Veins Clinical Policy Bulletin

Policy CodePolicy 0050

Change TypeNo material change

Effective DateNov 20, 1995

Last ReviewJul 28, 2023

Next Review DateJan 11, 2024

Key ActionObtain and document a Doppler/duplex ultrasound within 6 months showing junctional reflux duration and vein diameter and confirm selection criteria before authorizing varicose vein interventions.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes in this update (has_material_change=false).

1995Policy effective since

4.5 mmVein diameter threshold

>=500 msReflux duration threshold

Varithena/AscleraFDA approvals noted

multiple RCTsEvidence sources

Coverage Summary

Policy Number: 0050; Status: CURRENT. Effective date: 1995-11-20; Last review: 2023-07-28; Next review: 2024-01-11.

Scope: Defines medical necessity, experimental/investigational, and cosmetic coverage positions for surgical ligation/division/stripping, endovenous ablation (radiofrequency and laser), sclerotherapy (liquid/foam), ambulatory phlebectomy/Transilluminated powered phlebectomy (TriVex), valvular reconstruction, and treatment of incompetent perforating veins; includes required diagnostic duplex/Doppler ultrasound documentation and numeric thresholds for reflux duration and vein diameter, and lists applicable CPT/HCPCS/ICD-10 codes.

Coverage stance summary: Mixed — many primary saphenous procedures and adjunctive treatments are considered medically necessary when prespecified ultrasound, symptom/complication, and size thresholds are met; various newer or less-proven techniques and procedures are designated experimental/investigational (not covered) or cosmetic (not covered) for small veins or indications that do not cause medical problems.

Key numeric thresholds and policy facts

Junctional reflux duration>= 500 ms

Saphenous vein diameter (below junction)>= 4.5 mm

Perforator vein diameter

Policy Summary

PayerAetna

PolicyVaricose Veins Clinical Policy Bulletin

Policy CodePolicy 0050

Change TypeNo material change

Effective DateNov 20, 1995

Last ReviewJul 28, 2023

Next Review DateJan 11, 2024

SourceLink

On This Page

Medical-Necessity Criteria

Medically Necessary - Primary saphenous procedures (ligation/stripping, VNUS, ELAS/EVLT)

Medically Necessary - Primary saphenous procedures (ligation/stripping, VNUS, ELAS/EVLT). Covered when ALL of the following are met:

ALL of the following

Incompetence at the saphenofemoral junction or saphenopopliteal junction documented by recent Doppler or duplex ultrasound (performed within the past 6 months).
AND
- Ultrasound-documented junctional reflux duration of 500 milliseconds (ms) or greater in the saphenofemoral or saphenopopliteal vein to be treated.≥ 500 ms
- Vein size is 4.5 mm or greater in diameter measured by ultrasound below the saphenofemoral or saphenopopliteal junction (not valve diameter at junction).≥ 4.5 mm
- AND saphenous varicosities result in any of the following
  - Intractable ulceration secondary to venous stasis (CEAP C5/C6).
    Active or healed venous stasis ulceration meets clinical severity requirement.
  - More than one episode of minor hemorrhage from a ruptured superficial varicosity; or a single significant hemorrhage from a ruptured superficial varicosity (e.g., requiring transfusion).
  - OR symptoms despite conservative management
    Recurrent superficial thrombophlebitis.
    Severe and persistent pain and swelling interfering with activities of daily living.

Provider Actions and Billing Guidance

Documentation Required

Ultrasound documentation required

Doppler or duplex ultrasound performed within the past 6 months documenting junctional incompetence/reflux and vein diameter is required prior to varicose vein treatment; scans may also be used after treatment to assess success and detect thrombosis.

Prior Authorization

Medical necessity criteria must be met for coverage

Documentation that medical necessity selection criteria are met is required for coverage of interventions — including measured reflux duration (≥500 ms or ≥0.5 sec), vein diameter thresholds (eg, ≥4.5 mm for saphenous endovenous procedures), presence of qualifying symptoms or complications, and prior treatments or failed conservative care where applicable.

Billing Rule

Primary and secondary endovenous procedure coding per leg

For initial endovenous ablation treatment, one primary code and one secondary (add-on) code per affected leg are considered medically necessary; second and subsequent veins in the same extremity should be reported with the designated add-on CPT codes.

Documentation Required

Conservative management trial

A 3-month trial of conservative management (including prescription gradient support compression stockings) is generally required for symptomatic saphenous varicosities prior to intervention unless prior endovenous or stripping/division/ligation in the same leg makes conservative care unlikely to succeed.

A6530-A6549

Billing Rule

Sclerotherapy session limits

Medically necessary limits on sclerotherapy sessions: initially up to two sets of injections per affected leg (up to four sets if both legs affected); a set is multiple injections during a treatment session. Typical number of injections per session is usually 1–3 injections per vessel, treating up to 10–40 vessels or up to 20 injections per leg.

Documentation Required

Duplex ultrasound confirmation required

Duplex ultrasonography is required to map venous anatomy and confirm site and extent of saphenous reflux prior to endovenous catheter ablation; document reflux duration (≥0.5 seconds/≥500 ms) and saphenous vein diameter (≥4.5 mm for endovenous laser ablation).

Documentation Required

Conservative therapy exhaustion

Document that conservative measures were tried and that sclerotherapy is unlikely to provide successful results prior to performing EVLA/RFA (exception if prior endovenous ablation or stripping in same leg makes conservative care unlikely to succeed).

Billing Rule

TriVex billing

Transilluminated powered phlebectomy (TriVex) has no unique code in this policy and should be billed as other varicose vein removal procedures (i.e., as ambulatory phlebectomy/varicose vein removal).

Documentation Required

Contraindication screening

Screen for and document absence of absolute contraindications (eg, occlusive deep venous thrombosis, pregnancy) and assess relative contraindications (eg, arterial occlusive disease, hypercoagulability, tortuous veins, inability to ambulate) prior to EVLA/ELAS, RFA or SEPS.

Documentation Required

Risk assessment for peri-procedural anticoagulation

Perform an individualized VTE risk assessment to guide selective peri‑procedural pharmacologic prophylaxis (eg, using Caprini or equivalent); routine pharmacologic prophylaxis is not uniformly recommended and decisions should be individualized per guideline recommendations and risk factors.

Background and Use Considerations

Varicose veins are common; visible varicosities occur in a sizable fraction of adults and most are primarily a cosmetic issue and respond to conservative measures such as properly fitted compression stockings, exercise, leg elevation, and activity modification.

Pre-treatment Doppler or duplex ultrasound mapping is required for localization of reflux and to individualize therapy because physical exam alone is unreliable; ultrasound documents junctional reflux duration and vein diameter to determine candidacy for endovenous or surgical interventions.

Conservative management (compression and lifestyle measures) typically resolves or improves symptoms for many patients; surgical or endovenous interventions are reserved for patients with complications or persistent symptomatic disease or when conservative/sclerotherapy approaches are unlikely to succeed.

For venous leg ulcers, randomized trial evidence supports early endovenous ablation plus compression versus deferred intervention: early ablation shortened median time to healing (median 56 vs 82 days) and increased the 24-week healing rate (85.6% vs 76.3%), demonstrating benefit of earlier intervention in selected ulcer patients.

Evidence Summary

Study / Source	Key finding
Gohel et al. (EVRA/EVRA-like trial)
Early endovenous ablation shortened median time to venous ulcer healing (56 vs 82 days) and increased 24‑week healing rate (85.6% vs 76.3%)
Brittenden et al. (CLASS trial, RCT, 2014)
At 6 months ~80% complete ablation for laser and surgery vs ~43% for foam; laser had fewer procedural complications (1%) vs surgery (7%) and foam (6%)
Rasmussen et al. (2011 RCT)
1‑year patent/reflux rates: Laser 5.8% patent & refluxing, RFA 4.8%, Foam 16.3%, Stripping 4.8%; RFA and foam associated with faster recovery and less short‑term pain
Morrison et al. (VeClose RCT; VenaSeal vs RFA; 2015, 2017, 2019, 2020 extension)
At 3 months closure CAE 99% vs RFA 96% (non‑inferior); 12–36–60 month follow‑up shows sustained high occlusion (≈94%+) and non‑inferiority to RFA; similar QOL and no late device‑related serious AEs
Proebstle multicenter European cohort (eSCOPE) and single‑arm studies (Almeida et al. 2017, Gibson & Ferris 2017)
12‑month freedom from re‑canalization ~92.9% (Proebstle); 36‑month occlusion ~94.7% (Almeida single‑arm); small cohorts reported high early occlusion and QOL improvements; phlebitic reactions up to ~11–20%
Dimech & Cassar systematic review / pooled NBCA data (2020)
Pooled 2‑year occlusion: NBCA ~93.7% vs RFA 90.9% and EVLA 91.5%; fewer complications with NBCA in pooled data; QOL improvements comparable
Kolluri et al. (2020) network meta‑analysis (20 RCTs, 4,570 patients)
VenaSeal ranked highest for anatomical success at 6 months (probability p=0.980) and lower AE occurrence relative to other interventions in the network analysis
ClariVein / MOCA evidence (multiple cohorts and RCTs: Witte, Deijen, Bootun, Lane, others)
Short‑term occlusion rates often high (eg, pooled 6‑month MOCA ~94.7%); MOCA associated with less intra‑procedural pain and faster recovery but some studies show slightly higher re‑canalization vs RFA/EVLA and mixed longer‑term durability
Veith/other comparisons and systematic reviews (Cochrane, meta‑analyses)
Thermal ablation (EVLA/RFA) shows >90% short‑term occlusion in many studies and comparable mid‑term durability; EVLA/RFA considered at least as effective as surgery
VANISH / polidocanol RCTs and Varithena evidence (Todd et al., Varithena FDA approval)
Polidocanol microfoam (Varithena) superior to placebo for symptoms and appearance; Varithena FDA‑approved for incompetent GSV/accessory varicosities; comparative long‑term durability vs thermal ablation limited
Economic / guideline syntheses (CLASS cost‑effectiveness, NICE, Marsden et al.)
CLASS and economic analyses: EVLA/ETA often favored for clinical outcomes and cost‑effectiveness; EVLA considered treatment of choice for suitable patients in some analyses
Safety themes across studies
Common AEs: phlebitis (up to ~20%), bruising; rare DVT/PE reported; differences in complication profiles between modalities (eg, less ecchymosis with CAE)
Evidence limitations noted
Many studies are single‑arm cohorts or have modest follow‑up; some RCTs have drop‑outs and heterogeneity in definitions/timepoints; longer‑term head‑to‑head data remain limited

Definitions

Endovenous catheter ablation (EVCA): Non-specific term for catheter-based minimally invasive alternatives to surgical stripping including radiofrequency endovenous occlusion (VNUS) and endovenous laser ablation (ELAS/EVLT).

Set of injections (sclerotherapy): Multiple sclerotherapy injections during a single treatment session.

EVCA (abbreviation): Endovenous catheter ablation, includes EVLA/ELAS and radiofrequency ablation (RFA).

AP (ambulatory phlebectomy): Outpatient phlebectomy performed under local anesthesia (also called microphlebectomy).

SEPS: Subfascial endoscopic perforator vein surgery.

CAC / CAE / ECGA / NBCA: Cyanoacrylate adhesive closure / cyanoacrylate embolization / endovenous cyanoacrylate glue ablation / n-butyl cyanoacrylate (glue-based vein closure modalities).

MPFF: Micronized Purified Flavonoid Fraction, an oral phlebotropic drug therapy.

VCSS: Venous Clinical Severity Score.

CEAP: Clinical, Etiology, Anatomy, and Pathophysiology classification for venous disease (Clinical classes C0–C6r).

MOCA: Mechanochemical endovenous ablation (e.g., ClariVein) combining mechanical endothelial injury with liquid sclerosant.

GSV: Great saphenous vein.

SSV: Small saphenous vein.

EVLA / EVLT: Endovenous laser ablation (endovenous laser treatment).

RFA: Radiofrequency ablation.

Sclerotherapy: Endovenous chemical ablation.

Phlebectomy: Procedure using a small scalpel or needle to remove varicose veins.

CEAP Clinical Classification: C0 no signs; C1 telangiectasias/reticular veins; C2 varicose veins; C3 edema; C4a/b/c skin changes; C5 healed ulcer; C6 active venous ulcer (with recurrent variants noted).

Varicose Veins Clinical Policy Bulletin

Sign up for Aetna Policy 0050 alerts

Coverage Summary

Medical-Necessity Criteria

Not Covered / Experimental / Cosmetic

Provider Actions and Billing Guidance

Coding

Background and Use Considerations

Evidence Summary

Definitions

Revision History